Cited 99 times in
Immunotherapy in the treatment of non-small cell lung cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 조병철 | - |
dc.date.accessioned | 2015-01-06T17:13:48Z | - |
dc.date.available | 2015-01-06T17:13:48Z | - |
dc.date.issued | 2014 | - |
dc.identifier.issn | 0169-5002 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/99580 | - |
dc.description.abstract | Advances in the understanding of the role of the immune system in tumor immunosurveillance have resulted in the recognition that tumors can evade immune destruction via the dysregulation of co-inhibitory or checkpoint signals. This has led to the development of a generation immunotherapeutic agents targeting the immune checkpoint pathway. Recent early phase studies of immune checkpoint modulators, such as CTLA-4, PD-1 and PD-L1 inhibitors in NSCLC have reported promising results with prolonged clinical responses and tolerable toxicity. This article provides an overview of co-stimulatory and inhibitory molecules that regulate the immune response to tumors, recent therapies that have been developed to exploit these interactions and the role of predictive biomarkers in treatment selection. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 101~109 | - |
dc.relation.isPartOf | LUNG CANCER | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Animals | - |
dc.subject.MESH | Antibodies, Monoclonal/therapeutic use | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung/genetics | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung/immunology* | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung/metabolism | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung/therapy* | - |
dc.subject.MESH | Carrier Proteins/metabolism | - |
dc.subject.MESH | Costimulatory and Inhibitory T-Cell Receptors/genetics | - |
dc.subject.MESH | Costimulatory and Inhibitory T-Cell Receptors/metabolism | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Immunotherapy* | - |
dc.subject.MESH | Lung Neoplasms/genetics | - |
dc.subject.MESH | Lung Neoplasms/immunology* | - |
dc.subject.MESH | Lung Neoplasms/metabolism | - |
dc.subject.MESH | Lung Neoplasms/therapy* | - |
dc.subject.MESH | Protein Binding | - |
dc.title | Immunotherapy in the treatment of non-small cell lung cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Raghav Sundar | - |
dc.contributor.googleauthor | Richie Soong | - |
dc.contributor.googleauthor | Byoung-Chul Cho | - |
dc.contributor.googleauthor | Julie R. Brahmer | - |
dc.contributor.googleauthor | Ross A. Soo | - |
dc.identifier.doi | 10.1016/j.lungcan.2014.05.005 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A03822 | - |
dc.relation.journalcode | J02174 | - |
dc.identifier.eissn | 1872-8332 | - |
dc.identifier.pmid | 24880938 | - |
dc.identifier.url | http://www.sciencedirect.com/science/article/pii/S0169500214002141 | - |
dc.subject.keyword | CTLA-4 | - |
dc.subject.keyword | Immunotherapy | - |
dc.subject.keyword | Ipilimumab | - |
dc.subject.keyword | Nivolumab | - |
dc.subject.keyword | Non-small cell lung cancer | - |
dc.subject.keyword | PD-L1 | - |
dc.contributor.alternativeName | Cho, Byoung Chul | - |
dc.contributor.affiliatedAuthor | Cho, Byoung Chul | - |
dc.rights.accessRights | free | - |
dc.citation.volume | 85 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 101 | - |
dc.citation.endPage | 109 | - |
dc.identifier.bibliographicCitation | LUNG CANCER, Vol.85(2) : 101-109, 2014 | - |
dc.identifier.rimsid | 38932 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.